About mustang bio inc - MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.
MBIO At a Glance
Mustang Bio, Inc.
95 Sawyer Road
Waltham, Massachusetts 02453
| Phone | 1-781-652-4500 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -1,921,000.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.751 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 5.207 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
MBIO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -480,250.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MBIO Liquidity
| Current Ratio | 2.223 |
| Quick Ratio | 2.223 |
| Cash Ratio | 2.182 |
MBIO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -14.282 |
| Return on Equity | -67.928 |
| Return on Total Capital | -20.16 |
| Return on Invested Capital | -63.212 |
MBIO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |